Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found no significant association between androgenetic alopecia and metabolic syndrome, though systolic blood pressure was higher in the alopecia group compared to controls.

This study identified 30 new compounds with significant androgen receptor binding affinity through a combination of virtual screening and in vitro testing.

This study found that phyto-vesicles of ß-sitosterol showed better absorption and improved activity for treating androgenetic alopecia in rats compared to the compound and its complex.

In this study, men with androgenetic alopecia had lower BMI and waist-to-hip ratios than controls, but no significant association with hypertension or other lifestyle factors was observed.

This study found increased oxidative stress in younger male patients with early-onset androgenetic alopecia compared to healthy peers, suggesting a potential role for antioxidants in their treatment.

This study found that early-onset androgenetic alopecia, especially with a vertex pattern, may be an independent risk factor for cardiovascular disease and metabolic syndrome in men.

Minoxidil effectively promotes hair regrowth in younger patients with small balding areas.

This review analyzes how androgens impact sexual desire and reproductive behaviors, emphasizing molecular interactions, but provides no new clinical results.

This review summarizes how common polymorphisms in androgen and estrogen receptor genes may influence aging-related symptoms and diseases in men, but it reports no new clinical results.

This review discusses current and emerging therapeutic strategies for androgenetic alopecia, noting limited evidence but suggesting areas such as prostaglandin analogs, PRP, and progenitor cell therapies as promising future directions.

This study found that dihydrotestosterone (DHT) suppresses prostaglandin E2 and TGF-β induced IGF-I gene promoter activity in osteoblasts, suggesting complex interactions among bone growth regulators and potential complications from anabolic steroid use.

In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.

This study found that Monascus cursory extraction reduced baldness, prostate hyperplasia, and tumor incidence in animal models of androgen-related diseases, suggesting it may be a promising new therapeutic candidate.

This study introduced a novel nonsteroidal androgen receptor antagonist that effectively controls sebum production in the golden Syrian hamster ear model through targeted follicular delivery.

This study found that combining microneedling with 5% minoxidil improved hair growth in Chinese men with androgenetic alopecia, possibly through activating the Wnt/β-catenin signaling pathway.

This study suggests that the gene rs27647 polymorphism may play a role in the pathogenesis of severe acne vulgaris in post-adolescent male patients.

This study used a newly validated method to find that one-year finasteride treatment resulted in no significant differences in urinary androgen and prostaglandin levels between male pattern baldness patients and normal controls.

This study found that brain-derived nerve factor protein expression was significantly increased in balding scalp samples from men with androgenetic alopecia, suggesting it may play a role in hair follicle regulation.

In this study, the researchers reported that finasteride's efficacy in treating female pattern hair loss in Japanese patients was not predictable based on CAG repeat numbers in the androgen receptor gene.

This review discusses the potential link between androgenetic alopecia and COVID-19 severity, examining the role of androgens and relevant treatments, but reports no new clinical results.

This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.

This study found that men with early-onset androgenetic alopecia and certain risk factors may have worse gonadal steroidogenesis and an increased likelihood of developing gonadal dysfunction, suggesting a male equivalent of polycystic ovarian syndrome.

This study observed that estrogen receptor β and androgen receptor expressions in the skin decline with age, more noticeably under sun exposure, suggesting a role in skin aging.

This study found that men without prostate cancer carrying the A-allele of SNP rs1204038 had a 65% higher risk of PSA levels above 3 ng/mL compared to those with the G-allele, increasing referrals for further examination.

Finasteride reduces testosterone conversion, progesterone lessens this, and levamisole enhances finasteride's effect.

This paper discusses androgenetic alopecia, its causes, synonyms, and patterns, but reports no new findings or clinical results.

This article discusses the potential for topical caffeine as a natural alternative for treating androgenetic alopecia due to its ability to penetrate skin, but it reports no new clinical findings.

This study found that the retinoid receptor and PPAR pathway are involved in hair follicle miniaturization in androgenetic alopecia, alongside androgen receptors.

In this study, nine male cases of androgenetic alopecia showed marked improvement after receiving systemic dexpanthenol treatment.

LLLT is a safe, promising hair loss treatment, but more research needed.